-
-
-
-
-
-
-
MIRA Pharmaceuticals expands Ketamir-2 licensing to worldwide rights
-
-
-
-
-
-
-
MIRA Pharmaceuticals Reports Mira-55 Shows No THC- or Rimonabant-Associated CNS Side Effects in Preclinical Studies
-
-
-
-
-
-
-
MIRA Pharmaceuticals sells 1.75M shares at 66% premium
-
-
-
-
-
-
-
Mira Pharma (MIRA) Reports Positive PTSD Data Demonstrating Ketamir-2 Restores Normalized Behavior in Stressed Animals
-
-
-
-
-
-
-
MIRA's Ketamir-2 study accepted for publication in peer-reviewed journal
-
-
-
-
-
-
-
MIRA Reports Clear Reversal of Anxiety-Related Behavior in Animal Model Using SKNY-1, an Oral Drug Candidate for Obesity and Nicotine Addiction Under Definitive Agreement for Acquisition
-
-
-
-
-
-
-
Mira Pharma (MIRA) says Ketamir-2 has been accepted for publication in Frontiers in Pharmacology
-
423,287 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

